<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951765</url>
  </required_header>
  <id_info>
    <org_study_id>XZP-3287-1002</org_study_id>
    <nct_id>NCT04951765</nct_id>
  </id_info>
  <brief_title>Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects</brief_title>
  <official_title>A Phase I Study to Examine the Effects of Low and High-fat Meals on Orally Administered XZP-3287 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanzhu Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanzhu Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability&#xD;
      of XZP-3287 administered after a high or low-fat meal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary PK Endpoints</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK Endpoints</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>AUC0-∞</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK Endpoints</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK measures</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK measures</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK measures</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK measures</measure>
    <time_frame>day 1~day 21</time_frame>
    <description>Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 14 days after last dose</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast</description>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast</description>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast</description>
    <arm_group_label>Arm F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Healthy male or female subjects aged 18 to 65 years (including 18 and 65);&#xD;
&#xD;
          2. Male body weight ≥50kg, female body weight ≥45kg, body mass index between 18 to 28&#xD;
             kg/m2 (inclusive).&#xD;
&#xD;
          3. No medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal system.&#xD;
&#xD;
          4. Subjects shall ake effective contraceptive measures voluntarily within 3 months from&#xD;
             the date of signing the informed consent form (for women, 2 weeks before trial&#xD;
             screening) to the date of the last medication.&#xD;
&#xD;
          5. Willing and able to comply with all scheduled visits, study procedures, and provides&#xD;
             written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic constitution and those with known allergy to XZP-3287 or similar drugs and&#xD;
             excipients&#xD;
&#xD;
          2. Abnormal clinical tests and clinical significance judged by the investigator&#xD;
&#xD;
          3. Frequent use of sedatives, sleeping pills or other addictive drugs within 6 months&#xD;
             before enrollment&#xD;
&#xD;
          4. History of drug use, or drug abuse screening positive&#xD;
&#xD;
          5. Those who had smoked more than 5 cigarettes per day on average in the 3 months before&#xD;
             the screening period or habitually used nicotine-containing products and were unable&#xD;
             to quit during the test period&#xD;
&#xD;
          6. Heavy drinking or regular drinking in the six months preceding the screening period&#xD;
&#xD;
          7. Use of any prescription drug or Chinese herbal medicine within 4 weeks prior to&#xD;
             enrollment, or use of any over-the-counter drug, any vitamin product, health care drug&#xD;
             within 14 days prior to enrollment;&#xD;
&#xD;
          8. Treatment with an investigational drug within 3 months&#xD;
&#xD;
          9. Participated in blood donation with blood donation volume ≥400 mL or received blood&#xD;
             transfusion within 3 months before screening.&#xD;
&#xD;
         10. Had a severe infection, trauma or major surgery within 4 weeks of screening&#xD;
&#xD;
         11. Gastrointestinal disorders causing clinically significant symptoms such as nausea,&#xD;
             vomiting, and diarrhea, or malabsorption syndromes&#xD;
&#xD;
         12. Pregnant or lactating women, or subjects cannot take strict contraceptive measures as&#xD;
             required.&#xD;
&#xD;
         13. Hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and&#xD;
             syphilis antibody, any of which are positive.&#xD;
&#xD;
         14. Allergic to any food ingredients or has special requirements on diet, cannot follow&#xD;
             the unified diet&#xD;
&#xD;
         15. habitual consumption of food or beverage containing methylxanthine, such as tea,&#xD;
             coffee, cola, chocolate and so on during the study period&#xD;
&#xD;
         16. habitual consumption of grapefruit juice during the study period&#xD;
&#xD;
         17. have difficulty in blood collection or cannot tolerate vein puncture for blood&#xD;
             collection&#xD;
&#xD;
         18. As determined by the investigator, the subject has other factors that are not suitable&#xD;
             for the study -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cuilan Xiao</last_name>
    <phone>0086-13699167610</phone>
    <email>xiaocuilan@xuanzhubio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Cao</last_name>
      <phone>0086-0532-82911767</phone>
      <email>Caoyu1767@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XZP-3287</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

